# ICMJE DISCLOSURE FORM

**Date:** 6/30/2025

**Your Name:** Gisela Gabernet

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/29/2025

**Your Name:** Jessica Maciuch

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/29/2025

**Your Name:** Jeremy P. Gygi

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2024

**Your Name:** John Moore

**Manuscript Title:** **A multi-omics recovery factor predicts long COVID in the IMPACC study**

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** Annmarie Hoch

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** Caitlin Syphurs

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 06/28/2025

**Your Name:** Tianyi Chu

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None**<br><br>Click the tab key to add additional rows. | |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| **3** | Royalties or licenses | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| **13** | Other financial or non-financial interests | ☒ **None** | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Naresh Doni Jayavelu

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** David B. Corry

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Farrah Kheradmand MD

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/30/2025

**Your Name:** Rafick P. Sekaly

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** Grace McComsey

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** Elias K Haddad

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** Charles B. Cairns

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | National Institutes of Health | Paid to institution |
| | | Bill & Melinda Gates Foundation | Paid to institution |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | National Institutes of Health | Paid to institution |
| | | Bill & Melinda Gates Foundation | Paid to institution |
| | | | |
| **3** | Royalties or licenses | ☐ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | bioMerieux | Scientific consultant paid to me. |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☐ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☐ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☐ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☐ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☐ **None** | |
| | | National Institutes of Health | DSMB of the NHLBI convalescent plasma study |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ **None** | |
| | | Board Chair, National Foundation of Emergency Medicine | Non-profit foundation to support emergency medicine research and investigators |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Nadine Rouphael

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | Flu Lab | Institution |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | Merck, Sanofi, Pfizer, Vaccine Company, Immorna | Institution |
| | | NIH | Institution |
| | | | |
| **3** | Royalties or licenses | ☐ **None** | |
| | | Uptodate | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | Krog | Self |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☐ **None** | |
| | | Virology Education, Medscape | Self |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☐ **None** | |
| | | Sanofi, Moderna | Self |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☐ **None** | |
| | | Moderna, Sanofi, Seqirus, Pfizer advisory boards | Self |
| | | EMMES, ICON, BARDA, CyanVac, Imunon, Micron Safety Committees | Self |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ **None** | |
| | | ARLG, CDC Pertussis Challenge advisory boards, UAB Immunology Institute advisory boards and DMID SMC for a Malaria Challenge Model | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☐ **None** | |
| | | Georgia Research Alliance | Institution |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/3/2025

**Your Name:** Ana Fernandez-Sesma

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/8/2025

**Your Name:** Viviana Simon

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☐ **None** | |
| | | The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays (the "Serology Assays") which lists Viviana Simon as co-inventor. | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** Jordan P. Metcalf, M.D.

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** Nelson Ivan Agudelo Higuita

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/9/2025

**Your Name:** Catherine L. Hough

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | NIH, CDC, ALA | Paid to institution |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☐ **None** | |
| | | Lectures at Brown, University of Colorado, UCLA, and Penn | Payments to me |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☐ **None** | |
| | | Multiple DSMBs | No payment |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ **None** | |
| | | American Thoracic Society Board of Directors 2023-2025 | No payment |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** William B Messer

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | R01AI145835 | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 08/18/2025

**Your Name:** Mark M. Davis

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None**  | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/8/2025

**Your Name:** Kari C. Nadeau

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | National Institute of Allergy and Infectious Diseases (NIAID) | To Institution |
| | | National Heart, Lung, and Blood Institute (NHLBI) | To Institution |
| | | National Institute of Environmental Health Sciences (NIEHS) | To Institution |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | Excellergy | |
| | | Regeneron | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☐ **None** | |
| | | Granulocyte-based methods for detecting and monitoring immune system disorders | |
| | | Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders | |
| | | Biological sample preparation device and methods of using the same | |
| | | Immune cell activation device and methods of using the same | |
| | | Mixed Allergen Compositions and Methods for Using the Same | |
| | | Methods of Isolating Allergen Specific Antibodies', 'Microfluidic devise and diagnostic methods for Basophil Activation', and 'Methods for detecting heavy metals in biological samples | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☐ **None** | |
| | | Aravax | |
| | | World Health Organization | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **11** | Stock or stock options | ☐ **None** | |
| | | Phylaxis | |
| | | IgGenix | |
| | | Seed Health | |
| | | ClostraBio | |
| | | Cour | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☐ **None** | |
| | | Immune Tolerance Network | National Scientific Committee member |
| | | National Institutes of Health (NIH) clinical research centers | National Scientific Committee member |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Bali Pulendran

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/9/2025

**Your Name:** Monica Kraft, MD

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | NIH NIAID U19AI25357 | NIH research grant paid to the University of Arizona and Icahn School of Medicine at Mount Sinai |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | NIH, ALA, Sanofi, Areteia | Grants paid to Icahn School of Medicine at Mount Sinai |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | Sanofi, Regeneron Chiesi, AstraZeneca, Kinaset, Genentech related to the treatment of asthma | Funds paid to me |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☐ **None** | |
| | | Sanofi, Regeneron, Chiesi, AstraZeneca, Genentech on asthma pathobiology and treatment | Funds paid to me |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☐ **None** | |
| | | Patents issued and pending – surfactant protein A peptidomimetics | No funds paid |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ **None** | |
| | | Council and Treasurer -Association of Professors of Medicine and Alliance for the Advancement of Internal Medicine (AAIM) | No funds paid |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☐ **None** | |
| | | Stock in RaeSedo, Inc. where I am co-founder and Chief Medical Officer; company is in preclinical development of an asthma therapeutic | No revenue – in preclinical development |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☐ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | Section editor, UptoDate for severe asthma | Funds paid to me |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Christian Bime

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Elaine F. Reed

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Joanna Schaenman

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | F2G, Merck, Moderna (site PI for research studies | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | MedCure and OneLegacy | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☐ **None** | |
| | | International Society for Heart and Lung Transplantation | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ **None** | |
| | | American Society for Transplantation Working Group on Older Patients | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** David J Erle

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | NIH NIAID | Funding to my institution |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/3/2025

**Your Name:** Carolyn Calfee

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ None | |
| | | NIH | Funding support for the IMPACC study and other studies related to COVID19 and/or ARDS, to institution |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | Roche-Genentech | Completed research grant to my institution related to observational cohort study of patients at risk for or with ARDS/sepsis |
| | | Quantum Leap Healthcare Collaborative | Ongoing research support to my institution to serve as biobank for clinical trial in COVID and subsequently ARDS |
| | | US DOD | Pending research support to my institution to participate in leadership and enrollment of US patients in clinical trial of phenotype-targeted therapies for ARDS (US-PANTHER) |
| | | | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **4** | Consulting fees | ☒ **None** | |
| | | Arrowhead | One time consulting fee for medical advisory board for this company regarding potential treatments for ARDS |
| | | | |
| | | Vasomune | Sporadic medical advisory role for company regarding potential therapy for ARDS |
| | | Gen1e Life Sciences | Sporadic medical advisory role for company regarding potential therapy for ARDS |
| | | Cellenkos | One time consulting fee for medical advisory board for this company regarding potential treatments for ARDS |
| | | Calcimedica | One time consulting fee for medical advisory board for this company regarding potential treatments for ARDS |
| | | EnliTISA | One time consulting fee for medical advisory board for this company regarding potential treatments for ARDS |
| | | Novartis | One time consulting fee for medical advisory board for this company regarding potential treatments for ARDS |
| | | Aerogen | One time consulting fee for medical advisory board for this company regarding potential treatments for ARDS |
| | | Boehringer Ingelheim | Sporadic medical advisory role for company regarding potential therapy for IPF |
| | | | |
| | | Merck | Sporadic medical advisory role for company regarding potential therapy for ARDS |
| | | Healios | advisory board fees for mesenchymal stromal cell product |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, | ☐ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| | speakers bureaus, manuscript writing or educational events | Fisher Paykel | spoke at a symposium at ESICM 2022 that Fisher Paykel supported |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☐ **None** | |
| | | Patent on metagenomic sequencing for sepsis diagnosis (co-recipient) | Licensee is Regents of University of California, no commercial value at present |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Mark Atkinson

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Scott C. Brakenridge M.D.

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Esther Melamed

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | K08 AA027837 05<br>R01 AI104870 09 | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | research funding from Babson Diagnostics | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | honorarium from Multiple Sclerosis Association of America | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | served on advisory boards of Genentech, Horizon,Teva, and VielaBio. | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Albert Shaw

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None**<br>NIH U19AI089992 | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None**<br>Boehringer Ingelheim | |
| | | NIH AI181379 | |
| | | Claude D. Pepper Older Americans Independence Center at Yale P30AG021342 | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☐ **None** | Methods of Assessing Risk and Treating COVID-19 (provisional application) |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** David A Hafler

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ None | |
| | | NIH U19 AI089992 HIPC Grant | |
| | | NIH P01 AI073748 | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | Genentech | To institution |
| | | Roche | To Institution |
| | | Bristol Myers Squibb | To Institution |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Alison D. Augustine

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Patrice M Becker

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Al Ozonoff

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Steven E Bosinger

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/8/2024

**Your Name:** Walter Eckalbar

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | ☐ | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | ☐ | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | ☐ | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Holden T. Maecker

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | NIAID, NIH | Grant to institution |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Seunghee Kim-Schulze

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** Hanno Steen

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | NIH funding, as detailed in the manuscript | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Kerstin Westendorf

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Bjoern Peters

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/2/2025

**Your Name:** Slim Fourati

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/28/2025

**Your Name:** Matthew C Altman

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/30/2025

**Your Name:** Ofer Levy MD, PhD

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | ARMR Sciences (company developing opioid overdose vaccines) | Co-founder and advisor (payments made to me) |
| | | Boston Children's Hospital | Named inventor on patents related to adjuvants and human in vitro model systems |
| | | GlaxoSmithKline (GSK) | Sponsored research and consultant. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | GlaxosmithKline (GSK) | Payments made to me |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☐ **None** | |
| | | Multiple law firms (medicolegal cases) | Expert witness- payments made to me |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☐ **None** | |
| | | Patents held by Boston Children's Hospital re vaccine adjuvants and human in vitro systems modeling vaccine action | Named inventor |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☐ **None** | |
| | | ARMR Sciences | Stock and stock options to me. |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/30/2025

**Your Name:** Kinga K Smolen

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Ruth R Montgomery

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | U19 AI 089992 | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| 3 | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/1/2025

**Your Name:** Joann Diray-Arce

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | 5 U19AI118608-04, U19AI168643 | institution |
| | | 75N93023C00040, UM1AI068614 | institution |
| | | 75N93019C00044 | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | | Immune System Sciences |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | American Society for Histocompatibility and Immunogenetics Annual Meeting | Travel support for me |
| | | International Neonatal and Maternal Immunization Symposium Meeting | Travel support for me |
| | | 18th Vaccine Congress | Travel support for me |
| | | International Network of Special Immunization Services meeting | Travel support for me |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/30/2025

**Your Name:** Steven Kleinstein

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | Peraton | I receive consulting fees related to providing subject-matter expertise to the ImmPort data repository. |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 7/21/2025

**Your Name:** Leying Guan

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 6/27/2025

**Your Name:** Lauren Ehrlich

**Manuscript Title:** A multi-omics recovery factor predicts long COVID in the IMPACC study

**Manuscript Number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ None | |
| | | 5R01AI104870-07S1 | |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | 5R01AI104870-07S1 | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.